ACM Global Officially Opens New Shanghai Lab Facility
News Sep 11, 2014
ACM Global Central Laboratory has announced the official opening of its recently acquired Shanghai lab facility. ACM Shanghai is an element of ACM Global’s acquisition of Phoenix Pharma Central Services Pte. Ltd (Phoenix PCS), a premier central laboratory services provider for Asia-Pacific clinical trials.
Leveraging existing staff and local knowledge from Phoenix PCS, the fully-operational lab enables ACM Global to provide support of clinical trials throughout Shanghai and beyond with increased speed and efficiency.
“The opening of our wholly-owned Shanghai lab facility follows the successful launch of ACM Singapore in June, further extending ACM Global’s network of operating labs in an increasingly important region for clinical research,” said Jerry Boxall, managing director, ACM Europe and Asia.
Boxall continued, “We are thrilled to operate the new Shanghai and Singapore facilities in parallel to our locations in the United States, United Kingdom and India, providing the same robust capabilities and standards in scientific expertise. By seamlessly integrating operations of both new and existing facilities, we’ve established a network of harmonized laboratories producing a single database of test data for all global projects.”
ACM Shanghai is 10,000 square feet in size and located within the Shanghai International Medical Zone of the city’s Pudong district. The purpose-designed lab facility houses cutting-edge instruments and equipment identical to ACM’s US and UK laboratories and provides a broad menu of safety and specialty testing, including chemistry, hematology, urinalysis, and immunology testing.
Lee Chiew Yan, PhD, FRCPath, who joined ACM Global from Phoenix PCS as Director, Singapore and China Operations, oversees both the ACM Shanghai and Singapore facilities, including all staff and operations. She brings more than 20 years of experience in central laboratory operations within the Asia-Pacific region.
The addition of ACM owned and operated laboratories in Shanghai and Singapore is the latest in a series of growth-driven investments made by ACM Global, which in 2013 moved its European laboratory operations into a new, purpose-built, and expanded facility in York, England.
Since 1994, ACM Global has provided central laboratory testing services to more than 2,300 clinical studies, involving more than 7,000 investigator sites in 60 countries, giving the company a broad range of global experience and an in-depth understanding of regional requirements.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE